Dr Christopher Rowe

Dr Christopher Rowe

Conjoint Lecturer

School of Medicine and Public Health

Career Summary

Biography

My undergraduate degree (MBBS, Hons1) was obtained in 2008 through the University of New South Wales.  After undertaking internship and residency throughout Hunter New England Local Health District, I have trained in Adult Internal Medicine, then Endocrinology at John Hunter Hospital, receiving Fellowship of the Royal Australasian College of Physicians in 2016.  I currently work as an Adult Endocrinologist at John Hunter Hospital. 

My research interests span both diabetes and endocrinology, and I am active in both basic science and clinical projects.

My current doctoral studies through the University of Newcastle School of Medicine and Public Health / Hunter Medical Research Institute are investigating new diagnostic and therapetic targets for thyroid cancer.  In particular, our group is examining the utility of the TSH receptor as a specific theranostic marker for drug delivery, in collaboration with the John Hunter Hospital Thyroid Cancer Multidisciplinary Team, the Hunter Cancer Biobank and Pathology North (Hunter).  I am also collaborating with Professor Hubert Hondermarck in the School of Biomedical Sciences and Pharmacy to study the role of neurotrophins as biomarkers of thyroid malignancy.

I am active in a number of clinical research projects studying the impact of visceral fat on insulin resistance in Type 1 and Type 2 Diabetes, and therapeutic strategies to mitigate this.

I am a current recipient of a Clinical Research Fellowship (Hunter New England Local Health District), and my recent research has been supported by the Hunter Cancer Research Alliance, Avant Mutual Group, the University of Newcastle, and the John Hunter Hospital Charitable Trust. 


Keywords

  • Endocrinology
  • Thyroid
  • Insulin resistance
  • Diabetes Mellitus
  • Pregnancy

Awards

Prize

Year Award
2016 Australian Diabetes Society Travel Grant (Outstanding Abstract)
Australian Diabetes Society (ADS)
2016 Australasian Diabetes in Pregnancy Society Travel Grant (Outstanding Abstract)
Australian Diabetes in Pregnancy Society (ADIPS)
2015 Endocrine Society (USA) Travel Grant (Outstanding Abstract)
The Endocrine Society
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (5 outputs)

Year Citation Altmetrics Link
2018 Faulkner S, Jobling P, Rowe CW, Rodrigues Oliveira SM, Roselli S, Thorne RF, et al., 'Neurotrophin Receptors TrkA, p75

© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear.... [more]

© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75 NTR , and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75 NTR was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75 NTR , and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75 NTR , and sortilin as potential therapeutic targets in thyroid cancer.

DOI 10.1016/j.ajpath.2017.09.008
Co-authors Christopher Oldmeadow, Phillip Jobling, Rick Thorne, Hubert Hondermarck, Xu Zhang, Chenchen Jiang, Marjorie Walker, John Attia
2017 Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, Smith R, 'Targeting the TSH receptor in thyroid cancer', Endocrine-Related Cancer, 24 R191-R202 (2017) [C1]

© 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The exis... [more]

© 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSH R has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.

DOI 10.1530/ERC-17-0010
Citations Scopus - 2Web of Science - 2
Co-authors Roger Smith, Jonathan Paul, Craig Gedye
2017 Rowe CW, Haider AS, Viswanathan D, Jones M, Attia J, Wynne K, Acharya S, 'Insulin resistance correlates with maculopathy and severity of retinopathy in young adults with Type 1 Diabetes Mellitus', Diabetes Research and Clinical Practice, 131 154-160 (2017) [C1]

© 2017 Elsevier B.V. Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-se... [more]

© 2017 Elsevier B.V. Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-sectional study at a regional Australian tertiary hospital. Retinal pathology, assessed by colour fundus photography, was correlated with two surrogate measures of IR: estimated Glucose Disposal Rate (eGDR) and Insulin Sensitivity Score (ISS), where lower scores reflect greater IR. Results 107 patients were recruited, with mean age 24.7¿years, 53% male, and mean duration of disease 10.8¿years. Mean eGDR scores (5.6¿vs 8.0 p¿ < ¿0.001) and ISS (4.7¿vs 7.9, p¿ < ¿0.001) were lower in subjects having at least moderate non-proliferative diabetic retinopathy (NPDR; relative to nil/mild-NPDR). Similarly, mean eGDR (4.2¿vs 6.2, p¿=¿0.001) and ISS (3.8¿vs 6.1, p¿=¿0.003) were lower in patients with maculopathy. Multivariate logistic regression m odelling was used to control for confounding. For retinopathy severity, a unit increase in eGDR or ISS (representing lower IR) was associated with a 50% decrease in odds of moderate-NPDR or worse (eGDR OR 0.5, 95%CI 0.32¿0.77, p¿=¿0.002; ISS OR 0.49, 95%CI 0.29¿0.84, p¿=¿0.01). A unit increase in eGDR or ISS was associated with a 46¿56% decrease in odds of maculopathy (eGDR OR 0.54, 95%CI 0.37¿0.81, p¿=¿0.003; ISS OR 0.44, 95%CI 0.22¿0.88, p¿=¿0.02). Conclusions IR correlates with more severe retinopathy in young adults with Type 1¿DM. This is the first description of a correlation between IR and maculopathy in Type 1¿DM, warranting further evaluation. Prospective studies examining whether reducing IR can improve microvascular complications are required.

DOI 10.1016/j.diabres.2017.06.022
Co-authors John Attia
2016 Rowe CW, Murray K, Woods A, Gupta S, Smith R, Wynne K, 'Management of metastatic thyroid cancer in pregnancy: risk and uncertainty', ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, (2016)
DOI 10.1530/EDM-16-0071
Co-authors Roger Smith
2016 Rowe CW, Bendinelli C, McGrath S, 'Charting a course through the CEAs: diagnosis and management of medullary thyroid cancer', Clinical Endocrinology, 85 340-343 (2016) [C3]
DOI 10.1111/cen.13114
Show 2 more journal articles

Conference (11 outputs)

Year Citation Altmetrics Link
2017 Marlow A, Rowe C, Anderson D, Wynne K, King BR, Smart CE, 'Children and young adults with type 1 diabetes are more overweight and obese than reference populations, and this worsens with age', Tasmania (2017)
Co-authors Carmel Smart
2017 Rowe C, King S, Tolosa J, Paul J, Gedye C, Smith R, 'Overexpression of the Sodium-Iodide Symporter in thyroid cancer co-existing with Graves¿ disease', Perth, Western Australia (2017)
Co-authors Roger Smith, Craig Gedye, Jonathan Paul
2017 Croker E, Tan HLE, Rowe C, 'Diabetic ketoacidosis (DKA) in patients on maintenance dialysis: case series and literature review', Perth, Western Australia (2017)
2017 Rowe C, Tolosa Gonzalez JT, Faulkner S, Paul JW, Gedye C, McGrath S, et al., 'The precursor for nerve growth factor (proNGF) is detectable in the rinse of fine needle aspiration biopsy of thyroid cancer', Boston, Massachussetts (2017)
Co-authors Hubert Hondermarck, Craig Gedye, Roger Smith, Jonathan Paul
2016 Rowe C, Wynne K, Acharya SA, 'High rates of obesity in young adults with type 1 diabetes.', Gold Coast (2016)
2016 Rowe C, Pain O, Ronthal R, Buckmaster C, Morrison S, Wynne K, 'Betamethasone leads to acute hyperglycaemia in women with GDM.', Gold Coast (2016)
2015 Rowe C, McGrath S, Smith R, 'Response of TSH-Secreting Pituitary Tumours to Somatostatin Analogues in Five Patients', San Diego, California (2015)
DOI 10.1210/endo-meetings.2015.BCHVD.11.SAT-256
Co-authors Roger Smith
2015 Rowe C, mcgrath S, 'Parathyroid Ultrasound As Screening Tool for Familial Hypocalciuric Hypercalcemia', San Diego, California (2015)
DOI 10.1210/endo-meetings.2015.BCHVD.11.SAT-256
2015 Rowe C, Wynne K, Luu J, Quach T, Jackel D, Perry L, Acharya S, 'Emergency Department (ED) utilisation in young adults with type 1 diabetes (T1D) under care of a tertiary clinic.', Adelaide (2015)
Co-authors Lin Perry
2014 Rowe C, McGrath SA, 'Pre-operative localisation of parathyroid adenoma with ultrasound and sestamibi scintigraphy in primary hyperparathyroidism ¿ review of single centre experience.', Melbourne, Australia (2014)
2013 Rowe C, Joshi T, Wynne K, 'Remembering Halsted ¿Mediastinal Mass Complicating Graves¿ disease', Madrid, Spain (2013)
Show 8 more conferences
Edit

Grants and Funding

Summary

Number of grants 6
Total funding $485,994

Click on a grant title below to expand the full details for that specific grant.


20181 grants / $397,500

Hunter Cancer Biobank$397,500

Funding body: NSW Health Pathology - Pathology North

Funding body NSW Health Pathology - Pathology North
Project Team Professor Marjorie Walker, Laureate Professor Rodney Scott, Conjoint Professor Stephen Ackland, Mrs Susan Goode, Doctor Pradeep Tanwar, Doctor Nikki Verrills, Professor Hubert Hondermarck, Doctor Simon King, Mr Ricardo Vilain, Associate Professor Nikola Bowden, Doctor Kelly Kiejda, Associate Professor Simon Keely, Doctor Christopher Rowe
Scheme Research Grant
Role Investigator
Funding Start 2018
Funding Finish 2019
GNo G1800704
Type Of Funding C2210 - Aust StateTerritoryLocal - Own Purpose
Category 2210
UON Y

20172 grants / $28,494

Hunter Cancer Resarch Alliance - Biomarkers and Targeted Therapies$15,000

Funding body: Hunter Cancer Research Alliance (HCRA)

Funding body Hunter Cancer Research Alliance (HCRA)
Project Team

Christopher Rowe, Hubert Hondermarck, Roger Smith, Shaun McGrath, Simon King, Marjorie Walker, John Attia

Scheme HCRA Implementation Flagship program
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

NSW Health Pathology - Pathology North$13,494

Funding body: NSW Health Pathology - Pathology North

Funding body NSW Health Pathology - Pathology North
Project Team

Christopher Rowe, Simon King, Tony Dill, Anna Price, Hubert Hondermarck, Roger Smith, Jorge Tolosa, Jonathan Paul

Scheme TARC
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding External
Category EXTE
UON N

20162 grants / $40,000

AVANT Doctors in Training Scholarship Scheme$25,000 $25,000

Funding body: AVANT Mutual Group

Funding body AVANT Mutual Group
Project Team

Christopher Rowe, Jonathan Paul, Jorge Tolosa, Roger Smith

Scheme Doctors in Training Scholarship Scheme
Role Lead
Funding Start 2016
Funding Finish 2016
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Hunter New England Clinical Research Fellowship$15,000

Funding body: Hunter New England Health

Funding body Hunter New England Health
Project Team

Christopher Rowe

Scheme Clinical Research Fellowship
Role Lead
Funding Start 2016
Funding Finish 2018
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

20151 grants / $20,000

NewDIAB - Understanding Type 1 Diabetes in Newcastle$20,000

Funding body: John Hunter Charitable Trust Grant

Funding body John Hunter Charitable Trust Grant
Project Team

Christopher Rowe, Shamasunder Acharya, Lin Perry, Katie Wynne

Scheme John Hunter Charitable Trust Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N
Edit

Dr Christopher Rowe

Position

Conjoint Lecturer
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email c.rowe@newcastle.edu.au
Phone (02) 4921 4380
Link Twitter

Office

Location John Hunter Hospital Campus

,
Edit